TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis

Annals of the Rheumatic Diseases

Volumn 72, Issue 8, 2013, Pages 1390-1399

  Zong, Mei ^a   Bruton, Joseph D ^b   Grundtman, Cecilia ^a,c   Yang, Huan ^d   Li, Jian Hua ^d   Alexanderson, Helene ^a   Palmblad, Karin ^a   Andersson, Ulf ^a   Harris, Helena E ^a   Lundberg, Ingrid E ^a   Westerblad, Håkan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYSTEINE; HIGH MOBILITY GROUP B1 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYOSIN HEAVY CHAIN; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISULFIDE BOND; FLEXOR DIGITORUM BREVIS MUSCLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; MUSCLE FATIGUE; MUSCLE FIBER CULTURE; MUSCLE TETANIC CONTRACTION; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; WILD TYPE;

AUTOIMMUNE DISEASES; CYTOKINES; DERMATOMYOSITIS; INFLAMMATION; POLYMYOSITIS;

ADULT; AGED; ANIMALS; CALCIUM; CELLS, CULTURED; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE FIBERS, SKELETAL; MYOSIN HEAVY CHAINS; MYOSITIS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; SARCOPLASMIC RETICULUM; TOLL-LIKE RECEPTOR 4;

EID: 84880132910     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202207     Document Type: Article

References (56)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82. (Pubitemid 37159295)
3. Fasth AE, Dastmalchi M, Rahbar A, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009;183:4792-9.
4. Grundtman C, Salomonsson S, Dorph C, et al. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007;56:674-87.
5. Li CK, Knopp P, Moncrieffe H, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009;175:1030-40.
6. Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-74. (Pubitemid 27200003)
7. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824-35. (Pubitemid 40852891)
8. Tateyama M, Nagano I, Yoshioka M, et al. Expression of tumor necrosis factor-alpha in muscles of polymyositis. J Neurol Sci 1997;146:45-51. (Pubitemid 27116052)
9. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007;57:768-77. (Pubitemid 46932082)
10. Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy-a systematic review. Rheumatology 2011;50:2113-24.
11. Nader GA, Dastmalchi M, Alexanderson H, et al. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med 2010;16:455-64.
12. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-62.
13. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011;29:447-91.
14. Lambert CP, Wright NR, Finck BN, et al. Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol 2008;105:473-8.
15. Lee WJ. IGF-I exerts an anti-inflammatory effect on skeletal muscle cells through down-regulation of TLR4 signaling. Immune Netw 2011;11:223-6.
16. Oliveira AG, Carvalho BM, Tobar N, et al. Physical exercise reduces circulating lipopolysaccharide and TLR4 activation and improves insulin signaling in tissues of DIO rats. Diabetes 2011;60:784-96.
17. Zanchi NE, Lira FS, de Siqueira Filho MA, et al. Chronic low frequency/low volume resistance training reduces pro-inflammatory cytokine protein levels and TLR4 mRNA in rat skeletal muscle. Eur J Appl Physiol 2010;109:1095-102.
18. Frost RA, Nystrom GJ, Lang CH. Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am J Physiol Regul Integr Comp Physiol 2006;290:R773-84.
19. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010;107:11942-7.
20. Grundtman C, Bruton J, Yamada T, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010;24:570-8.
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
22. Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol 1996;23:1380-4. (Pubitemid 26258761)
23. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43:49-54. (Pubitemid 38088368)
24. Alexanderson H, Stenstrom CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology 1999;38:608-11. (Pubitemid 29507327)
25. Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;57:694-702. (Pubitemid 46764062)
26. Heikkilä S, Viitanen JV, Kautiainen H, et al. Rehabilitation in Myositis. Physiotherapy 2001;87:301-9. (Pubitemid 32600740)
27. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol 2001;28:1591-9. (Pubitemid 32660633)
28. Ulfgren AK, Grundtman C, Borg K, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004;50:1586-94. (Pubitemid 38608081)
29. Li J, Wang H, Mason JM, et al. Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods 2004;289:211-23. (Pubitemid 38900918)
30. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51. (Pubitemid 29329996)
31. Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012;209:1519-28.
32. Yang H, Lundbäck P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of HMGB1. Mol Med 2011;18:250-9.
33. Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: cellular mechanisms. Physiol Rev 2008;88:287-332.
34. 2+ in living cells. Adv Exp Med Biol 2012;740:27-43.
35. van der Pas J, Hengstman GJ, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004;75:136-9. (Pubitemid 38091283)
36. Englund P, Nennesmo I, Klareskog L, et al. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002;46:1044-55. (Pubitemid 34303818)
37. 2+ in single intact muscle fibres from transgenic mice. J Physiol 2003;552:833-44. (Pubitemid 37428424)
38. Huttunen HJ, Fages C, Kuja-Panula J, et al. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002;62:4805-11.
39. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001. (Pubitemid 35256475)
40. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5. (Pubitemid 34773774)
41. Kalovidouris AE. Dysfunction of the sarcoplasmic reticulum in polymyositis. Arthritis Rheum 1984;27:299-304. (Pubitemid 14163223)
42. Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol 2009;21:581-7.
43. Tsung A, Klune JR, Zhang X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007;204:2913-23. (Pubitemid 350179560)
44. Hamada T, Torikai M, Kuwazuru A, et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008;58:2675-85.
45. Cardinal J, Pan P, Dhupar R, et al. Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology 2009;50:565-74.
46. Sachdev U, Cui X, Hong G, et al. High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J Vasc Surg 2012;55:180-91.
47. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343-56. (Pubitemid 20132049)
48. Estruch R, Grau JM, Fernandez-Sola J, et al. Microvascular changes in skeletal muscle in idiopathic inflammatory myopathy. Hum Pathol 1992;23:888-95.
49. Grundtman C, Tham E, Ulfgren AK, et al. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008;58:3224-38.
50. Probst-Cousin S, Neundorfer B, Heuss D. Microvasculopathic neuromuscular diseases: lessons from hypoxia-inducible factors. Neuromuscul Disord 2010;20:192-7.
51. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637-42. (Pubitemid 44036267)
52. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci 2004;101:296-301. (Pubitemid 38084244)
53. Li J, Gong Q, Zhong S, et al. Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2011;26:469-78.
54. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-43. (Pubitemid 40524681)
55. Fan J, Li Y, Levy RM, et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol 2007;178:6573-80. (Pubitemid 46717441)
56. Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010;16:413-19.